Cognitive impairment is a leading component of several neurodegenerative and
neurodevelopmental diseases, profoundly impacting on the individual, the family, and …

INTRODUCTION Blood tests have the potential to improve the accuracy of Alzheimer's
disease (AD) clinical diagnosis, which will enable greater access to AD‐specific treatments …

Previous studies have suggested that systemic viral infections may increase risks of
dementia. Whether this holds true for severe acute respiratory syndrome coronavirus 2 …

Blood-based biomarkers are minimally invasive tools to detect the pathological changes of
Alzheimer's Disease (AD). This meta-analysis aims to investigate the use of blood-derived p …

Alzheimer's disease (AD) is a progressive irreversible neurodegenerative disorder that
represents a major global public health concern. Traditionally, AD is diagnosed using …

Alzheimer's disease (AD) affects more women than men. Although women live longer than
men, it is not longevity alone, but other factors, including metabolic changes, that contribute …

Background: As the burden of Alzheimer's disease (AD) escalates with an ageing
population, the demand for early and accessible diagnostic methods becomes increasingly …

Background Mild cognitive impairment (MCI) is a clinical diagnosis representing early
symptom changes with preserved functional independence. There are multiple potential …

INTRODUCTION Blood‐based biomarkers (BBMs) can enable early detection of brain
amyloid beta (Aβ) pathology in cognitively unimpaired individuals. However, the extent to …

Plasma biomarkers for Alzheimer's disease (AD) are increasingly being used to assist in
making an etiological diagnosis for cognitively impaired (CI) individuals or to identify …